Hutchison China MediTech Ltd.

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment covers all activities related to oncology/immunology including sales, marketing, manufacturing and research and development with respect to drugs and drug candidates. The Other Ventures segment includes all other HUTCHMED businesses. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

– Late-Breaking Abstract of the positive SANET-ep Phase III trial of surufatinib in patients with non-pancreatic neuroendocrine tumors (“NET”) to be presented –

Chi-Med Highlights Presentation of Clinical Data from the Successful SANET-ep Phase III Trial at ESMO Annual Meeting

LONDON, Sept.  18, 2019  (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (AIM/Nasdaq: HCM) shares additional analyses from three completed and ongoing clinical studies of fruquintinib and savolitinib at the 22nd Annual Meeting of the Chinese Society of Clinical Oncology (“CSCO”) on September 18 to 22, 2019 in Xiamen, China.

Chi-Med Highlights Oral Presentations at 2019 CSCO Annual Meeting

LONDON, Sept.  03, 2019  (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executive Officer, will participate in a fireside chat at Morgan Stanley 17th Annual Global Healthcare Conference on Wednesday, September 11, 2019 at 9:55 am (EDT) in New York, NY. 

Chi-Med to Participate in the Morgan Stanley 17th Annual Global Healthcare Conference

LONDON, Sept.  03, 2019  (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (AIM/Nasdaq: HCM) has initiated an international Phase I/Ib study of HMPL-689, its novel, highly selective and potent small molecule phosphoinositide-3 kinase delta isoform (“PI3Kδ”) inhibitor, in patients with relapsed or refractory lymphoma.  The first patient was dosed on August 26, 2019 in the U.S.

Chi-Med Initiates an International Phase I/Ib Trial of HMPL-689 in Patients with Advanced Relapsed or Refractory Lymphoma

LONDON, Aug.  23, 2019  (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated a Phase I study of HMPL-523, its novel spleen tyrosine kinase (“Syk”) inhibitor, in patients with immune thrombocytopenia (“ITP”), an autoimmune disorder that can lead to increased risk of bleeding. The first ITP patient was dosed on August 12, 2019 in China.

Chi-Med Initiates a Phase I Trial of HMPL-523 in Patients with Immune Thrombocytopenia (ITP) in China

Hutchison China MediTech Ltd (HCM) CEO Christian Hogg on Q2 2019 Results - Earnings Call Transcript

The pricing of a secondary offering is weighing heavily on the Chinese drug stock.

News for Hutchison China MediTech Ltd. Stock (HCM)